Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IGN101: Phase II data

In a double-blind, placebo-controlled Phase II trial in 53 evaluable patients

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE